MedTrace Logo

Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes

NCT02801448 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2022-01-19

No results posted yet for this study

Summary

Type 2 diabetes (T2D) results from a combination of insufficient insulin secretion from pancreatic islets and insulin resistance of target cells. The investigators have extensive pre-clinical data suggesting that BSE through its high content of the isothiocyanate sulforaphane improves hepatic insulin sensitivity. BSE as a dietary supplement could therefore benefit both patients with T2D and individuals at risk for the disease. BSE-containing sulforaphane is suggested to activate Nuclear factor-like 2 (NRF2). The investigators aim to study the clinical effect of using BSE as a dietary supplement on glucose tolerance and insulin sensitivity.

Conditions

  • Diabetes Mellitus, Non-Insulin-Dependent

Interventions

DRUG

sulforaphane

sulforaphane-containing broccoli sprout extracts

DRUG

Placebo

Maltodextrine-based placebo without sulforaphane

Sponsors & Collaborators

  • Anders Rosengren, MD PhD

    lead OTHER

Principal Investigators

  • Anders Rosengren · Lund University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2020-06-30
Completion
2020-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02801448 on ClinicalTrials.gov